Publication of the 2021 Annual Financial Report

Paris (France), April 28, 2022 – 6.00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the publication of the Company’s 2020 annual financial report.

The 2021 annual financial report is available to the public on the Company’s website.